Bausch Health Offers Insight on RED-C Clinical Trials Results
Bausch Health Companies Inc. (NYSE: BHC) has shared pivotal insights regarding the global Phase 3 RED-C clinical trials. These studies were notably focused on evaluating amorphous-rifaximin solid soluble dispersion (SSD) for patients grappling with liver cirrhosis, aiming primarily at the prevention of hepatic encephalopathy (HE). Despite the safety and tolerability of the treatment, the trials did not achieve the key primary endpoint that researchers had hoped for.
Disappointments and Commitment to Further Research
“We are disappointed in the results, as there is currently no approved treatment for these patients,” Thomas J. Appio, the Chief Executive Officer of Bausch Health, stated. He also emphasized the company's dedication to evaluating the extensive dataset from the trials to uncover potential new avenues for development in the healthcare space. This determination highlights Bausch Health's ongoing commitment to enhancing treatment options for patients faced with serious health challenges.
Overview of the RED-C Program
The RED-C program is significant in its scope, comprising two large-scale, randomized, double-blind, placebo-controlled Phase 3 trials. Over 1,000 patients participated across 398 sites in 17 countries, all focusing on assessing the efficacy of rifaximin SSD in delaying the onset of HE for adults with liver cirrhosis who had not previously experienced such episodes. This extensive study aims to gather crucial data for developing safer therapeutic options in liver disease management.
Understanding Cirrhosis and Its Implications
Cirrhosis represents a major factor contributing to end-stage liver disease. From statistical findings, it ranks as the ninth leading cause of death, based on data from relevant health authorities. As the disease progresses, patients may face several debilitating symptoms including hepatic encephalopathy, jaundice, ascites, or variceal hemorrhage. The urgent need for effective treatments is glaringly evident from these statistics.
About Bausch Health
Bausch Health, known for enriching lives through a relentless drive toward better health outcomes, operates as a diversified global pharmaceutical company. The firm specializes in developing, manufacturing, and marketing a wide range of products mainly covering various therapeutic areas such as gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, and eye health through its significant involvement with Bausch + Lomb Corporation. Their long-term vision is to establish themselves as a reliable, integrated healthcare company valued by patients, healthcare professionals, and investors alike.
Frequently Asked Questions
What is the outcome of the RED-C Phase 3 trial?
The RED-C Phase 3 trial's outcome was disappointing as it did not meet its primary endpoint, despite the treatment being safe and well-tolerated.
What does Bausch Health plan to do next?
Bausch Health is currently reviewing the full dataset from the RED-C trials to explore potential new development opportunities in the treatment of hepatic encephalopathy.
How many patients were involved in the RED-C trials?
Over 1,000 patients participated in the RED-C trials, which were conducted across 398 sites in 17 countries.
What is cirrhosis?
Cirrhosis is a serious liver condition that can lead to significant complications such as hepatic encephalopathy and represents a major cause of severe health crises in patients.
What areas does Bausch Health focus on?
Bausch Health focuses on a range of therapeutic areas including gastroenterology, hepatology, neuroscience, dermatology, aesthetics, and eye health.
